These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

141 related items for PubMed ID: 15081078

  • 1. An economic evaluation of a European cohort from a multinational trial of linezolid versus teicoplanin in serious Gram-positive bacterial infections: the importance of treatment setting in evaluating treatment effects.
    Nathwani D, Li JZ, Balan DA, Willke RJ, Rittenhouse BE, Mozaffari E, Tavakoli M, Tang T.
    Int J Antimicrob Agents; 2004 Apr; 23(4):315-24. PubMed ID: 15081078
    [Abstract] [Full Text] [Related]

  • 2. Hospital resource use and cost of treatment with linezolid versus teicoplanin for treatment of serious gram-positive bacterial infections among hospitalized patients from South America and Mexico: results from a multicenter trial.
    López H, Li JZ, Balan DA, Willke RJ, Rittenhouse BE, Mozaffari E, Vidal G, Zitto T, Tang T.
    Clin Ther; 2003 Jun; 25(6):1846-71. PubMed ID: 12860502
    [Abstract] [Full Text] [Related]

  • 3. Linezolid compared with teicoplanin for the treatment of suspected or proven Gram-positive infections.
    Wilcox M, Nathwani D, Dryden M.
    J Antimicrob Chemother; 2004 Feb; 53(2):335-44. PubMed ID: 14729745
    [Abstract] [Full Text] [Related]

  • 4. Impact of linezolid on economic outcomes and determinants of cost in a clinical trial evaluating patients with MRSA complicated skin and soft-tissue infections.
    McKinnon PS, Sorensen SV, Liu LZ, Itani KM.
    Ann Pharmacother; 2006 Jun; 40(6):1017-23. PubMed ID: 16720705
    [Abstract] [Full Text] [Related]

  • 5. Linezolid versus teicoplanin in the treatment of Gram-positive infections in the critically ill: a randomized, double-blind, multicentre study.
    Cepeda JA, Whitehouse T, Cooper B, Hails J, Jones K, Kwaku F, Taylor L, Hayman S, Shaw S, Kibbler C, Shulman R, Singer M, Wilson AP.
    J Antimicrob Chemother; 2004 Feb; 53(2):345-55. PubMed ID: 14711840
    [Abstract] [Full Text] [Related]

  • 6. Economic evaluation of linezolid versus teicoplanin for the treatment of infections caused by gram-positive microorganisms in Spain.
    Grau S, Aguado JM, Mateu-de Antonio J, Gonzalez P, Del Castillo A.
    J Chemother; 2007 Aug; 19(4):398-409. PubMed ID: 17855184
    [Abstract] [Full Text] [Related]

  • 7. Cost-effectiveness of linezolid versus vancomycin for hospitalized patients with complicated skin and soft-tissue infections in France.
    De Cock E, Sorensen S, Levrat F, Besnier JM, Dupon M, Guery B, Duttagupta S.
    Med Mal Infect; 2009 May; 39(5):330-40. PubMed ID: 19304423
    [Abstract] [Full Text] [Related]

  • 8. Pharmacoeconomic evaluation of linezolid versus teicoplanin in bacteremia by Gram-positive microorganisms.
    Grau S, Mateu-de Antonio J, Soto J, Marín-Casino M, Salas E.
    Pharm World Sci; 2005 Dec; 27(6):459-64. PubMed ID: 16341954
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Linezolid reduces length of stay and duration of intravenous treatment compared with vancomycin for complicated skin and soft tissue infections due to suspected or proven methicillin-resistant Staphylococcus aureus (MRSA).
    Itani KM, Weigelt J, Li JZ, Duttagupta S.
    Int J Antimicrob Agents; 2005 Dec; 26(6):442-8. PubMed ID: 16289514
    [Abstract] [Full Text] [Related]

  • 18. In vitro susceptibility of Gram-positive pathogens to linezolid and teicoplanin and effect on outcome in critically ill patients.
    Wilson AP, Cepeda JA, Hayman S, Whitehouse T, Singer M, Bellingan G.
    J Antimicrob Chemother; 2006 Aug; 58(2):470-3. PubMed ID: 16735420
    [Abstract] [Full Text] [Related]

  • 19. Linezolid treatment for gram-positive infections: a retrospective comparison with teicoplanin.
    Tascini C, Gemignani G, Doria R, Biancofiore G, Urbani L, Mosca C, Malacarne P, Papineschi F, Passaglia C, Dal Canto L, Procaccini M, Furneri G, Didoni G, Filipponi F, Menichetti F.
    J Chemother; 2009 Jun; 21(3):311-6. PubMed ID: 19567352
    [Abstract] [Full Text] [Related]

  • 20. Randomized, double-blind comparison of once-weekly dalbavancin versus twice-daily linezolid therapy for the treatment of complicated skin and skin structure infections.
    Jauregui LE, Babazadeh S, Seltzer E, Goldberg L, Krievins D, Frederick M, Krause D, Satilovs I, Endzinas Z, Breaux J, O'Riordan W.
    Clin Infect Dis; 2005 Nov 15; 41(10):1407-15. PubMed ID: 16231250
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.